Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Martí JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Ahmadi T, Liu W, Wang J, Chastain K, Vermeulen J, Krevvata M, Lopez-Masi L, Carey J, Rowe M, Carson R, Zweegman S
- DOI
- 10.1038/s41591-024-03485-7
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-21
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/310f825c-fb7d-4cf2-b286-5b9a6a4fcd3d is authoritative.
How this rating was calculated
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary endpoint is minimal residual disease (MRD) negativity, a surrogate biomarker, not a hard clinical outcome. Although the paper reports a significant improvement in progression-free survival (PFS), the primary efficacy claim is based on MRD negativity. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data) nor does it cite validated evidence linking MRD negativity to clinical outcomes in this context, despite mentioning its use as an accelerated approval endpoint.
“The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10 − 5 by next-generation sequencing.”
- 02Treatment effect not shown to be clinically meaningful
The primary effect size is the difference in MRD-negativity rates: 60.9% with D-VRd versus 39.4% with VRd (odds ratio 2.37). While statistically significant, the clinical meaningfulness of this surrogate improvement is not anchored to a minimal clinically important difference or a direct patient-centered outcome. The PFS improvement (HR 0.57) is reported but is a secondary endpoint and not the primary basis for the efficacy claim.
“the MRD-negativity rate was 60.9% with D-VRd versus 39.4% with VRd (odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55; P < 0.0001)”
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted and transparently reported phase 3 randomized clinical trial. The manuscript demonstrates strong scientific premise, rigorous design, comprehensive reporting of biological variables, ethical approvals, key resources, statistical methods, data availability, and transparency. Only minor reporting gaps (e.g., explicit CONSORT statement) and copyedit issues were identified.
Both reviewers independently scored all eight dimensions and agreed on 'pass' for each. The study type is interventional (randomized controlled trial). The statistics verification covered only 2 tests (limited to those with test statistics/df or effect estimates with CIs); other reported statistics were not machine-verified. The citation check found no retracted or unresolved references. The reproducibility check confirmed both data links are live.
Numerical inconsistencies
None foundValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
Checked — nothing surfaced.
Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.
- CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Primary endpoint MRD-negativity rate odds ratio p-value
“the MRD-negativity rate was 60.9% with D-VRd versus 39.4% with VRd (odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55; P < 0.0001)”
Taken as given: The MRD-negativity rates are 60.9% and 39.4% of the ITT populations (197 and 198).; The counts are rounded to the nearest integer: 0.609*197=120.0, 0.394*198=78.0.; The p-value is from a two-sided Fisher's exact test on the 2x2 table.Method: Recomputed two-sided Fisher's exact test p-value from the 2x2 table derived from the reported percentages and group sizes.How we recomputed it: pFisher2x2(120, 77, 78, 120) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2PFS hazard ratio p-value
“D-VRd significantly improved PFS compared with VRd, with a hazard ratio of 0.57 (95% CI, 0.41–0.79; P = 0.0005)”
Taken as given: The hazard ratio is a ratio estimate (log scale).; The 95% CI is two-sided.; The p-value is derived from the Wald test using the log hazard ratio and its standard error.Method: Recomputed two-sided p-value from the hazard ratio and 95% CI using the normal approximation.How we recomputed it: pCI(0.57, 0.41, 0.79, 1)
Overstated conclusions
3 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions only partially backed by the presented evidenceAssessed
7 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.
- partialReviewers 1, 2D-VRd quadruplet therapy is a new standard of care for transplant-ineligible or transplant-deferred NDMM.The efficacy and safety data support the claim, but the overall survival data are immature and the claim of 'standard of care' may be considered a strong conclusion.Evidence: Improved MRD, PFS, and safety profile consistent with known profiles.
“The present study supports D-VRd quadruplet therapy as a new standard of care for transplant-ineligible or transplant-deferred NDMM.”
AbstractFind in source - supportedReviewers 1, 2D-VRd significantly improves MRD-negativity rate compared to VRd.The primary endpoint result is statistically significant with a large effect size and narrow CI.Evidence: MRD-negativity rate 60.9% vs 39.4%, OR 2.37 (95% CI 1.58-3.55), P<0.0001.
“the MRD-negativity rate was 60.9% with D-VRd versus 39.4% with VRd (odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55; P < 0.0001)”
AbstractFind in source - supportedReviewers 1, 2D-VRd significantly improves progression-free survival compared to VRd.The PFS hazard ratio is statistically significant and consistent across subgroups.Evidence: HR 0.57 (95% CI 0.41-0.79), P=0.0005.
“Risk of progression or death was 43% lower for D-VRd versus VRd (hazard ratio, 0.57; 95% CI, 0.41–0.79; P = 0.0005)”
AbstractFind in source - supportedReviewer 1D-VRd produces deeper and more durable MRD responses than VRd.Sustained MRD-negativity rate is significantly higher with D-VRd.Evidence: Sustained MRD-negativity rate 48.7% vs 26.3%, OR 2.63 (95% CI 1.73-4.00), P<0.0001.
“Rates of ≥CR (81.2% versus 61.6%; P < 0.0001) and sustained MRD negativity (≥12 months; 48.7% versus 26.3%; P < 0.0001) were significantly higher with D-VRd versus VRd.”
AbstractFind in source - supportedReviewer 2D-VRd significantly improves ≥CR rate compared with VRd.The ≥CR rate is reported with a significant odds ratio and p-value.Evidence: Abstract: 'Rates of ≥CR (81.2% versus 61.6%; P < 0.0001)'
“Rates of ≥CR (81.2% versus 61.6%; P < 0.0001)”
AbstractFind in source - supportedReviewer 2D-VRd significantly improves sustained MRD-negativity rate compared with VRd.The sustained MRD-negativity rate is reported with a significant odds ratio and p-value.Evidence: Abstract: 'sustained MRD negativity (≥12 months; 48.7% versus 26.3%; P < 0.0001)'
“sustained MRD negativity (≥12 months; 48.7% versus 26.3%; P < 0.0001)”
AbstractFind in source - supportedReviewer 2The safety profile of D-VRd is consistent with known profiles of the individual agents.The safety data are presented and discussed, with no unexpected toxicities.Evidence: Abstract: 'Adverse events were consistent with the known safety profiles for daratumumab and VRd.'
“Adverse events were consistent with the known safety profiles for daratumumab and VRd.”
AbstractFind in source
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary endpoint is minimal residual disease (MRD) negativity, a surrogate biomarker, not a hard clinical outcome. Although the paper reports a significant improvement in progression-free survival (PFS), the primary efficacy claim is based on MRD negativity. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data) nor does it cite validated evidence linking MRD negativity to clinical outcomes in this context, despite mentioning its use as an accelerated approval endpoint.
“The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10 − 5 by next-generation sequencing.”
- INADEQUATEEffect sizeThe primary effect size is the difference in MRD-negativity rates: 60.9% with D-VRd versus 39.4% with VRd (odds ratio 2.37). While statistically significant, the clinical meaningfulness of this surrogate improvement is not anchored to a minimal clinically important difference or a direct patient-centered outcome. The PFS improvement (HR 0.57) is reported but is a secondary endpoint and not the primary basis for the efficacy claim.
“the MRD-negativity rate was 60.9% with D-VRd versus 39.4% with VRd (odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55; P < 0.0001)”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
None foundRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
Checked — nothing surfaced.
The introduction cites multiple prior studies establishing the efficacy of daratumumab-based regimens and VRd as standard of care, and the rationale for the CEPHEUS trial is clearly stated. The paper acknowledges limitations of prior work, such as the need for quadruplet therapy in transplant-ineligible patients and the context of the COVID-19 pandemic.
“Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes.”
“The phase 3 CEPHEUS study evaluated quadruplet D-VRd versus VRd alone in patients with NDMM who were transplant ineligible or for whom transplant was not planned as the initial therapy (transplant deferred).”
“Sensitivity analyses provided stronger evidence of the treatment effect of D-VRd on overall survival after adjusting for the impact of COVID-19.”
“Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes. For transplant-ineligible patients, significant progression-free survival (PFS) benefit was observed with frontline daratumumab plus lenalidomide and dexamethasone (D-Rd) triplet therapy versus lenalidomide and dexamethasone (Rd) alone in the phase 3 MAIA study”
“The phase 3 CEPHEUS study evaluated quadruplet D-VRd versus VRd alone in patients with NDMM who were transplant ineligible or for whom transplant was not planned as the initial therapy (transplant deferred).”
Randomization was performed using randomly permuted blocks via an interactive web-response system, stratified by ISS stage and age/transplant eligibility. The sponsor remained blinded at interim analyses. A power analysis was conducted to detect a 15% difference in MRD-negativity rate. Inclusion/exclusion criteria are detailed. Outlier handling is addressed through the pre-specified analysis population (ITT) and sensitivity analyses. Controls are inherent in the randomized comparator arm. Independent replication is not applicable for a single pivotal trial.
“Patients were randomly assigned (1:1) to D-VRd or VRd by randomly permuted blocks using an interactive web-response system.”
“At both the primary MRD analysis and interim PFS analysis, the Independent Data Monitoring Committee recommended continuing the study unmodified and the sponsor remained blinded.”
“We estimated that a sample size of 360 patients (180 in each arm) was needed to achieve 80% power to detect a 15% treatment difference in overall MRD-negativity rate at a two-sided alpha of 0.05.”
“Patients were randomly assigned (1:1) to D-VRd or VRd by randomly permuted blocks using an interactive web-response system.”
“We estimated that a sample size of 360 patients (180 in each arm) was needed to achieve 80% power to detect a 15% treatment difference in overall MRD-negativity rate at a two-sided alpha of 0.05.”
“At both the primary MRD analysis and interim PFS analysis, the Independent Data Monitoring Committee recommended continuing the study unmodified and the sponsor remained blinded.”
The paper reports sex, age, race, ECOG performance status, frailty score, ISS stage, and cytogenetic risk in Table 1. Since both sexes are enrolled, sex_justified is not applicable. Age, weight, and health status are reported via ECOG and frailty scores. Species/strain and housing conditions are not applicable for a human trial.
“Male sex, no. (%) b | 87 (44.2) | 111 (56.1)”
“The median patient age was 70 years (range 31–80 years); 28.1% had International Staging System (ISS) stage III disease, and 13.2% had high cytogenetic risk (t(4;14), t(14;16) or del(17p)).”
“Male sex, no. (%) b | 87 (44.2) | 111 (56.1)”
“Median (range) (years) | 70 (42–79) | 70 (31–80)”
The paper states that an independent ethics committee or institutional review board approved the protocol at each site, and all patients provided written informed consent. Regulatory compliance with ICH-GCP and the Declaration of Helsinki is stated.
“An independent ethics committee or institutional review board approved the protocol at each site.”
“All patients provided written informed consent.”
“The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the principles originating from the Declaration of Helsinki and study site-specific regulations.”
“An independent ethics committee or institutional review board approved the protocol at each site.”
“All patients provided written informed consent.”
“The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the principles originating from the Declaration of Helsinki and study site-specific regulations.”
The trial uses a drug combination, so the bench criteria (antibodies, cell lines, mycoplasma, organisms) are not applicable. The investigational products are adequately identified with doses and schedules. The MRD assay (clonoSEQ) is identified. Statistical software (SAS 9.4) is identified.
“All patients received eight 21-day cycles of VRd, consisting of subcutaneous bortezomib (1.3 mg m −2 on days 1, 4, 8 and 11), oral lenalidomide (25 mg on days 1–14) and oral or intravenous dexamethasone (20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 (days 1, 4, 8 and 11 if aged >75 years or body mass index <18.5 kg m −2 ))”
“All statistical analyses were performed using SAS Software 9.4 (TS1M6 MBCS3170).”
“All patients received eight 21-day cycles of VRd, consisting of subcutaneous bortezomib (1.3 mg m −2 on days 1, 4, 8 and 11), oral lenalidomide (25 mg on days 1–14) and oral or intravenous dexamethasone (20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12”
“MRD was evaluated via next-generation sequencing using the clonoSEQ assay”
“All statistical analyses were performed using SAS Software 9.4 (TS1M6 MBCS3170).”
The paper names the statistical tests (Cochran–Mantel–Haenszel, log-rank, Cox regression) and reports exact p-values (e.g., P < 0.0001) and effect sizes with 95% CIs. Assumptions are handled by design (stratified tests, hierarchical testing). Data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility is not applicable for large-N continuous outcomes.
“Overall MRD-negativity rates and rates of ≥CR were compared between groups using the stratified Cochran–Mantel–Haenszel test.”
“odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55”
“Overall MRD-negativity rates and rates of ≥CR were compared between groups using the stratified Cochran–Mantel–Haenszel test. Time-to-event endpoints, including PFS, were compared between groups using a stratified log(rank test).”
“odds ratio, 2.37; 95% confidence interval (CI), 1.58–3.55”
The data availability statement provides a concrete route for data access through the YODA Project, which is a managed-access platform. Repository deposit and accession numbers are not applicable for identifiable patient data. Code sharing is not applicable as no bespoke code was written; the study used electronic Case Report Forms and SAS.
“requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at http://yoda.yale.edu”
“The data sharing policy of Johnson & Johnson is available at https://innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency . As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at http://yoda.yale.edu .”
The trial is registered (NCT03652064). Methods are detailed enough for replication. Limitations are discussed, including underrepresentation of Black patients and COVID-19 impact. Conclusions are proportional to the evidence. Funding and competing interests are disclosed.
“ClinicalTrials.gov registration: NCT03652064”
“A potential limitation of the CEPHEUS study is that patients who are Black or African American represented 4.8% of the total study population, which in some countries may be an underrepresentation.”
“The present study was sponsored by Johnson & Johnson.”
“ClinicalTrials.gov registration: NCT03652064”
“A potential limitation of the CEPHEUS study is that patients who are Black or African American represented 4.8% of the total study population, which in some countries may be an underrepresentation.”
“The present study was sponsored by Johnson & Johnson.”
Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 29 references by DOI: 1 verified — 28 no DOI (shown, not verified).
- NO DOIDaratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumorsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDirect in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAntibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linkingNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDaratumumab depletes CD38 + immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHigh-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of actionNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDeep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumabNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDaratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIOverall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIBortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDARZALEX (daratumumab) injection (package insert)No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDaratumumab plus lenalidomide and dexamethasone for untreated myelomaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIFinal survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA studyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDaratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myelomaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIBortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOILonger term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDaratumumab plus bortezomib, melphalan, and prednisone for untreated myelomaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDaratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIANo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDaratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 MAIA studyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIIsatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myelomaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIFrontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myelomaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIMultiple myeloma: patient outcomes in real-world practiceNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIRedefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysisNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIInternational Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIConsensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIInternational Myeloma Working Group updated criteria for the diagnosis of multiple myelomaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIGeriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIClosed testing procedures for group sequential clinical trials with multiple endpointsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
2 data/code links checked; 2 live.
- datahttps://innovativemedicine.jnj.com/our-innovation/clinical-trials/transparencyLIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttp://yoda.yale.eduLIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
3 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 3 minor suggestions below.
3 copyedit issues flagged: mostly typo, consistency, grammar.
- MINORtypoAbstract“Some 395 patients”→ A total of 395 patientsInformal phrasing.
- MINORconsistencyResults, Patients and treatment“197 and 198 assigned to D-VRd and VRd, respectively”→ 197 assigned to D-VRd and 198 to VRdClarity.
- MINORgrammarDiscussion“the ultimate decision probably based on”→ the ultimate decision is probably based onMissing verb.
The published work is robust and well-reported. An informed reader should weigh the open-label design and the underrepresentation of Black patients as limitations, but these are adequately discussed. No erratum or correction appears warranted based on the checks performed; the minor reporting gaps (explicit CONSORT statement, data access timeframe) are worth noting but do not undermine the conclusions.
- 1.MEDIUMreportingIn the Methods or a dedicated section, explicitly state adherence to the CONSORT reporting guideline for randomized trials, including the version used.The paper currently does not mention a reporting guideline, which is a standard expectation for clinical trials and would strengthen transparency.
- 2.MEDIUMdata codeIn the Data Availability section, clarify the timeframe and conditions for data access requests via the YODA Project.The current statement lacks specific conditions or timelines, which would help readers understand the access process.
- 3.MEDIUMreportingIn the Discussion, explicitly acknowledge the open-label design as a limitation and discuss potential bias from lack of blinding.Open-label trials are susceptible to bias, and explicitly acknowledging this preempts concerns and improves balanced reporting.
- 4.MEDIUMreportingIn the Discussion, expand the statement on generalizability to address underrepresentation of Black/African American patients and other minorities.The current brief mention may not fully address the implications of limited diversity for the applicability of the findings.
- 5.LOWcopyeditIn the Abstract, change 'Some 395 patients' to 'A total of 395 patients'.The original phrasing is informal and less precise for a scientific manuscript.
- 6.LOWcopyeditIn Results, Patients and treatment, rephrase '197 and 198 assigned to D-VRd and VRd, respectively' to '197 assigned to D-VRd and 198 to VRd'.The suggested phrasing is clearer and avoids potential confusion.
- 7.LOWcopyeditIn the Discussion, correct the grammar: 'the ultimate decision probably based on' to 'the ultimate decision is probably based on'.The original sentence is missing a verb, which is a grammatical error.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.